Advanced search
Publication Cover
Cancer Investigation Volume 32, 2014 - Issue 9
Submit an article Journal homepage
143
Views
0
CrossRef citations to date
0
Altmetric
Original Article

Docetaxel in Castration-Resistant Prostate Cancer: A Single-Centre Experience

Detti BeatriceDepartment of Radiation-Oncology, University of Florence, Florence, Italy,
,
Franceschini DavideDepartment of Radiation-Oncology, University of Florence, Florence, Italy,Correspondence[email protected]
,
Saieva CalogeroMolecular and Nutritional Epidemiology Unit, Cancer Research and Prevention Center (ISPO), Florence, Italy
,
Di Brina LuciaDepartment of Radiation-Oncology, University of Florence, Florence, Italy,
,
Baki MohammedDepartment of Radiation-Oncology, University of Florence, Florence, Italy,
,
Meattini IcroDepartment of Radiation-Oncology, University of Florence, Florence, Italy,
,
Di Cataldo VanessaDepartment of Radiation-Oncology, University of Florence, Florence, Italy,
,
Monteleone Pasquetti EleonoraDepartment of Radiation-Oncology, University of Florence, Florence, Italy,
,
Furfaro IlariaDepartment of Radiation-Oncology, University of Florence, Florence, Italy,
,
Mancuso AnnaDepartment of Radiation-Oncology, University of Florence, Florence, Italy,
,
Simontacchi GabrieleDepartment of Radiation-Oncology, University of Florence, Florence, Italy,
&
Livi LorenzoDepartment of Radiation-Oncology, University of Florence, Florence, Italy,
 show all
Pages 445-450 | Received 14 May 2014, Accepted 09 Aug 2014, Published online: 26 Sep 2014
 
Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days

Abstract

We present a single-institution experience reporting the efficacy and safety of docetaxel, administered as first-line chemotherapy, in castration-resistant prostate cancer (CRPC), focusing on patients and treatment parameters.

From November 2004 to January 2012, 51 patients received chemotherapy with docetaxel. With a mean follow-up time (from the beginning of CHT) of 1.6 years (range 0.1–5.1 years), 35 patients (68.6%) died for prostate cancer and 48 patients (94.1%) showed progression of the disease.

Five factors influenced overall survival: nodal status at diagnosis, neoadjuvant hormonal therapy, number of cycles of docetaxel administered, schedule of docetaxel and ECOG performance status before starting chemotherapy.

View correction statement:
Docetaxel in Castration-Resistant Prostate Cancer: A Single-Centre Experience

Log in via your institution

Access through your institution

Log in to Taylor & Francis Online

Restore content access

Restore content access for purchases made as guest
Purchase options * Save for later

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 65.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 1,193.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.